AN
ANNX.US Annexon Inc
- Market cap
- USD 748M
- P/E
- -
- P/B
- 5.30x
- ROE
- -140.7%
- Dividend yield
- 0.25%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ANNX.US undervalued?
Graham numberThe Graham number of Annexon Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Annexon Inc fundamental analysis
No fundamental analysis for Annexon Inc yet.
Annexon Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is als…
Full company profileAnnexon Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Annexon Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -271K | -488K | -493K | -667K | -3.41M | -3.31M | -3.27M | -3.45M | -3.69M | - |
| Operating Income | -20.5M | -19.1M | -32.5M | -63.5M | -131M | -146M | -144M | -154M | -216M | -207M |
| EBITDA | -20.2M | -18.7M | -32.0M | -62.8M | -129M | -143M | -132M | -136M | -205M | -197M |
| Net Income | -18.7M | -18.3M | -37.2M | -62.7M | -128M | -138M | -134M | -138M | -207M | -201M |
| EPS | -0.49 | -1.60 | -0.97 | -3.70 | -3.34 | -2.53 | -1.77 | -1.01 | -1.33 | -0.98 |
| Balance Sheet | ||||||||||
| Total Assets | 7.82M | 48.1M | 49.9M | 356M | 287M | 285M | 298M | 350M | 278M | 250M |
| Total Liabilities | 54.0M | 10.3M | 6.37M | 11.7M | 55.1M | 53.9M | 47.1M | 57.0M | 65.9M | 108M |
| Shareholders' Equity | -46.2M | 37.9M | 43.5M | 344M | 232M | 231M | 251M | 293M | 212M | 143M |
| Cash & Short-term Investments | 2.97M | 44.2M | 43.9M | 351M | 243M | 243M | 260M | 312M | 238M | 213M |
| Total Debt | 49.0M | 107M | - | - | 34.6M | 32.9M | 31.4M | 29.0M | 26.2M | 73.2M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -19.3M | -17.2M | -28.4M | -53.1M | -106M | -116M | -121M | -118M | -186M | -191M |
| Capital Expenditure | 567K | 17.0K | 267K | 464K | 1.65M | 6.53M | 193K | 15.0K | 137K | 183K |
| Free Cash Flow | -19.8M | -17.2M | -28.6M | -53.6M | -108M | -123M | -121M | -118M | -186M | -191M |
| Ratios | ||||||||||
| ROE | - | -48.3% | -85.4% | -18.2% | -55.1% | -59.8% | -53.6% | -47.2% | -97.7% | -140.7% |
| ROA | -239.2% | -38.0% | -74.5% | -17.6% | -44.5% | -48.5% | -45.1% | -39.5% | -74.5% | -80.2% |
| Debt to Equity | - | 2.83x | - | - | 0.15x | 0.14x | 0.13x | 0.10x | 0.12x | 0.51x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Annexon Inc dividends
- Dividend yield
- 0.25%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 1.86M | 0.01 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 103M | 6.04 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Annexon Inc
- Insiders 0.44%
- Institutions 99.57%
- Public & others 0.00%
- Shares outstanding 191M
- Free float 174M
Top funds holding ANNX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 6.27M | 3.31% | +2.69% | Oct 2026 |
| Fidelity Select Biotechnology | 6.17M | 3.26% | 0.00% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 5.72M | 3.02% | +15.10% | Sep 2026 |
| iShares Russell 2000 ETF | 3.97M | 2.10% | 0.00% | Oct 2026 |
| Fidelity Stock Selector Small Cap | 2.19M | 1.16% | +6.06% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 2.10M | 1.11% | +61.07% | Sep 2026 |
| Columbia Acorn Inst | 1.81M | 0.96% | -0.38% | Sep 2026 |
| Fidelity Small Cap Growth | 1.79M | 0.94% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 1.70M | 0.90% | +0.31% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 1.66M | 0.88% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 1.48M | 0.78% | -0.38% | Oct 2026 |
| Columbia Small Cap Value Discv A | 1.41M | 0.74% | +0.73% | Sep 2026 |
| Foord International B | 1.25M | 0.66% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 1.25M | 0.66% | -2.42% | Oct 2026 |
| Columbia Small Cap Growth Inst | 1.22M | 0.64% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 1.20M | 0.63% | 0.00% | Aug 2026 |
| Fidelity Series Small Cap Opps | 1.13M | 0.60% | -4.40% | Aug 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1.11M | 0.58% | +0.27% | Oct 2026 |
| Fidelity Small Cap Discovery | 1.05M | 0.56% | +7.64% | Aug 2026 |
| Fidelity Select Pharmaceuticals Port | 1.00M | 0.53% | 0.00% | Sep 2026 |
Top institutions holding ANNX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 19.5M | 10.30% | +83.52% | Jun 2026 |
| BlackRock Inc | 13.5M | 7.14% | +23.78% | Jun 2026 |
| Redmile Group, LLC | 11.9M | 6.26% | -18.42% | Jun 2026 |
| State Street Corp | 9.82M | 5.18% | +41.99% | Jun 2026 |
| Bvf Inc | 8.70M | 4.59% | 0.00% | Jun 2026 |
| Woodline Partners LP | 6.93M | 3.65% | +196.31% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.87M | 3.62% | +15.35% | Jun 2026 |
| Mak Capital One LLC | 5.86M | 3.09% | +24.09% | Jun 2026 |
| The Goldman Sachs Group Inc | 5.83M | 3.07% | +170.59% | Jun 2026 |
| Siren, L.L.C. | 4.46M | 2.35% | +12.63% | Jun 2026 |
| Bain Capital Life Sciences Investors, LLC | 4.44M | 2.34% | -14.87% | Jun 2026 |
| Bellevue Group AG | 4.10M | 2.16% | -20.50% | Jun 2026 |
| Geode Capital Management, LLC | 4.04M | 2.13% | +19.52% | Jun 2026 |
| MPM Oncology Impact Management LP | 3.54M | 1.87% | 0.00% | Jun 2026 |
| Ameriprise Financial Inc | 3.51M | 1.85% | +1.75% | Jun 2026 |
| Great Point Partners LLC | 3.50M | 1.85% | +40.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 3.50M | 1.85% | -18.60% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.14M | 1.66% | +14.93% | Jun 2026 |
| Palo Alto Investors, LLC | 2.95M | 1.56% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 2.83M | 1.49% | -27.17% | Jun 2026 |
Annexon Inc company profile
- Company name
- Annexon Inc
- Ticker
- ANNX.US
- Exchange
- USA Stocks
- Listed since
- Jul 24, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 97
- Fiscal year end
- December
- Address
- 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005
- Phone
- 650 822 5500
- Website
- annexonbio.com
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Annexon Inc management
10- Mr. Douglas E. Love Esq., J.D.CEO, President & Director · born 1968
- Ms. Jennifer Lew CPAExecutive VP, CFO & Corporate Secretary · born 1973
- Dr. Ted Yednock Ph.D.Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board · born 1958
- Dr. Dean R. Artis Ph.D.Chief Scientific Officer & Executive VP · born 1961
- Ms. Linda A. FitzpatrickChief Human Resources Officer · born 1957
- Mr. Michael Overdorf M.B.A.Executive VP & Chief Business Officer · born 1971
- Mr. Henk-Andre Kroon M.D.Senior Vice President of Translational Medicine
- Dr. Jamie Dananberg M.D.Executive VP & Chief Medical Officer · born 1958
- Mr. Shikhar Agarwal M.B.A.Senior VP & Head of Commercial
- Dr. Sunil Mehta Pharm.D.Senior VP of Medical Affairs